|
시장보고서
상품코드
2078195
뮤코다당증(MPS) 치료 시장 : 치료법별, MPS 유형별, 최종사용자별, 지역별Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, By MPS Type, By End User, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) |
||||||
뮤코다당증(MPS) 치료 시장은 2026년에 30억 3,000만 달러, 2033년까지 60억 2,000만 달러에 이를 것으로 예상됩니다. 또한, 2026-2033년 CAGR 10.3%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 30억 3,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 10.30% | 2033년 시장 규모 예측 : | 60억 2,000만 달러 |
무코다당증(MPS)의 치료는 주로 증상 관리, 삶의 질 향상, 그리고 질병 진행을 늦추는 데 중점을 두고 있습니다. MPS는 이러한 복잡한 당류를 분해하는 특정 효소의 결핍으로 인해 세포나 조직 내에 글리코사미노글리칸(GAG)이 축적되는 것을 특징으로 하는 희귀 유전성 질환군입니다. 효소 보충 요법(ERT) : 이는 다양한 유형의 MPS에 대한 주요 치료법입니다. ERT에서는 결핍되거나 부족한 효소를 정맥 내로 투여하여 축적된 GAG의 분해를 돕습니다. ERT는 유익하지만, 효소가 혈액-뇌 장벽을 효율적으로 통과하지 못할 가능성이 있어 신경학적 증상을 효과적으로 치료하지 못할 수도 있습니다. 조혈모세포 이식(HSCT) : 골수 이식이라고도 불리는 HSCT는 기증자로부터 얻은 건강한 조혈모세포를 환자의 골수에 이식하는 치료법입니다. 기증자 유래 세포는 결핍된 효소를 생성할 수 있으므로, GAG의 축적을 줄일 가능성이 있습니다. HSCT는 중대하고 돌이킬 수 없는 손상이 발생하기 전인 질병의 초기 단계에서 시행될 때 가장 효과적입니다.
시장 역학
시장에 진출한 각 기업은 뮤코다당증(MPS) 치료를 위한 제휴 등 다양한 비유기적 성장 전략에 주력하고 있으며, 이는 전 세계 뮤코다당증(MPS) 치료 시장의 성장을 뒷받침할 것으로 예측됩니다. 예를 들어, 2021년 9월, “환자 중심이자 연구 개발 주도형”의 “더 나은 건강과 밝은 미래”의 실현을 위해 힘쓰고 있는 세계적인 바이오의약품 기업인 다케다 제약은 세계적인 전문 의약품 기업인 JCR 파마슈티컬스와 함께 헌터 증후군 치료를 목적으로 하는 인간 트랜스페린 수용체와 이드루네이트-2-설파타제(IDS) 효소를 표적으로 하는 차세대 재조합 융합 단백질인 임상시험용 의약품 ‘JR-141'의 상용화를 위한 독점적 제휴 및 라이선스 계약을 체결했습니다. 본 계약의 조건에 따라, 다케다 제약은 캐나다, 유럽 및 기타 지역(일본 및 아시아태평양의 특정 국가·지역 제외)에서 JR-141의 상용화를 진행합니다. JCR사는 미국 이외의 지역에서 체결된 이 라이선스 계약에 대해 계약 일시금을 수령하고, 추가적인 개발 및 상용화와 관련된 마일스톤 지급금, 그리고 향후 매출액에 따른 단계별 로열티를 수령할 권리를 보유합니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 뮤코다당증(MPS) 치료 시장의 주요 기업을 분석했습니다.
- 전 세계 뮤코다당증(MPS) 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 뮤코다당증(MPS) 치료 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 뮤코다당증(MPS) 치료 시장
제5장 세계의 뮤코다당증(MPS) 치료 시장 : 치료별, 2021년-2033년
제6장 세계의 뮤코다당증(MPS) 치료 시장 : MPS 유형별, 2021년-2033년
제7장 세계의 뮤코다당증(MPS) 치료 시장 : 최종사용자별, 2021년-2033년
제8장 세계의 뮤코다당증(MPS) 치료 시장 : 지역별, 2021년-2033년
제9장 경쟁 구도
제10장 섹션
LSH 26.07.10Mucopolysaccharidosis (MPS) Treatment Market is estimated to be valued at USD 3.03 Bn in 2026 and is expected to reach USD 6.02 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.03 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.30% | 2033 Value Projection: | USD 6.02 Bn |
The treatment of Mucopolysaccharidosis (MPS) is primarily focused on managing symptoms, improving the quality of life, and slowing down the progression of the disease. MPS is a group of rare genetic disorders characterized by the accumulation of glycosaminoglycans (GAGs) in cells and tissues due to deficiencies in specific enzymes responsible for breaking down these complex sugars. Enzyme Replacement Therapy (ERT): This is the mainstay treatment for many types of MPS. In ERT, the missing or deficient enzyme is administered intravenously to help break down the accumulated GAGs. Although ERT can be beneficial, it may not effectively treat neurological symptoms because the enzyme may not efficiently cross the blood-brain barrier. Hematopoietic Stem Cell Transplantation (HSCT): Also known as bone marrow transplantation, HSCT involves transplanting healthy stem cells from a donor into the patient's bone marrow. The donor cells can produce the missing enzyme, leading to a potential reduction in GAG accumulation. HSCT is most effective when performed early in the disease course before significant irreversible damage has occurred.
Market Dynamics
Market players are focusing on various inorganic growth strategies such as collaborations for the treatment mucopolysaccharidosis (MPS), which is expected to boost the global mucopolysaccharidosis (MPS) treatment market growth. For instance, In September 2021, Takeda Pharmaceuticals, a patient-focused, R&D-driven, global biopharmaceutical company committed to bringing Better Health and a Brighter Future, entered into an exclusive collaboration and license agreement with JCR Pharmaceuticals is a global specialty pharmaceuticals company, to commercialize JR-141, an investigational next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome. Under the terms of the agreement, Takeda commercialized JR-141 outside of the U.S., including Canada, Europe, and other regions (excluding Japan and certain other Asia Pacific countries). JCR received an upfront payment for such an ex-US license and is eligible to receive additional development and commercial milestones, as well as tiered royalties on potential sales.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global mucopolysaccharidosis (MPS) treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
- Global mucopolysaccharidosis (MPS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global mucopolysaccharidosis (MPS) treatment market.
Detailed Segmentation:
- Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment (Revenue, USD Bn, 2021 - 2033)
- Enzyme Replacement Therapy
- Stem Cell Therapy
- Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type (Revenue, USD Bn, 2021 - 2033)
- MPS-I
- MPS-II
- MPS-IV
- MPS-VI
- MPS-VII
- Others (MPS-III and MPS-IX)
- Global Mucopolysaccharidosis (MPS) Treatment Market, By End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Others
- Global Mucopolysaccharidosis (MPS) Treatment, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Takeda Pharmaceutical Company Limited
- BioMarin Pharmaceuticals, Inc.
- Ultragenyx Pharmaceutical Inc.
- Sarepta Therapeutics
- Abeona Therapeutics Inc.
- Eloxx Pharmaceuticals
- Esteve
- Immusoft Corporation
- Inventiva
- GC Pharma
- JCR Pharmaceuticals Co Ltd.
- RegenxBio Inc.
- Sangamo Therapeutics, Inc.
- Bioasis Technologies Inc.
- Paradigm Biopharmaceuticals Ltd.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By MPS Type
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Mucopolysaccharidosis (MPS) Treatment Market
- Economic Impact
- Impact on Supply and Demand
5. Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
- Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
6. Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- MPS-I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- MPS-II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- MPS-IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- MPS-VI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- MPS-VII
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Others (MPS-III and MPS-IX)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
7. Global Mucopolysaccharidosis (MPS) Treatment Market, By End User, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
8. Global Mucopolysaccharidosis (MPS) Treatment Market, By Region, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country/Region, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Takeda Pharmaceutical Company Limited
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BioMarin Pharmaceuticals, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Ultragenyx Pharmaceutical Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sarepta Therapeutics
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Abeona Therapeutics Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eloxx Pharmaceuticals
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Esteve
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Immusoft Corporation
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Inventiva
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GC Pharma
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- JCR Pharmaceuticals Co Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- RegenxBio Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sangamo Therapeutics, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bioasis Technologies Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Paradigm Biopharmaceuticals Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceutical Company Limited
10. Section
- References
- Research Methodology
- About us and Sales Contact
